Cardiogen (Cardiogen (Ala-Glu-Asp-Arg Cardiac Bioregulator))
A short synthetic peptide bioregulator from the Khavinson family targeted at cardiac (myocardial) tissue. It is used in the bioregulator community to support heart muscle function and cardiovascular resilience in short repeated courses.
How it works
As a signal peptide (Ala-Glu-Asp-Arg), it is proposed to regulate gene expression in myocardial tissue, supporting cardiomyocyte function, myocardial protein synthesis, and normal cardiac tissue maintenance.
Key facts
- Molecular weight: ~460 Da
- Half-life: Short (peptide)
- Bioavailability: Oral (encapsulated) or subcutaneous
- Storage: Room temperature (capsules) or refrigerate (injectable).
Dosing overview
- Typical dose: ~1-2 capsules/day or short injectable courses
- Frequency: Once daily
- Duration: 10-30 day courses
- Route: Oral capsule or subcutaneous
Protocol notes
- Taken as short repeatable courses (often 10-30 days), a few times per year.
- Oral encapsulated forms are taken once daily on an empty stomach.
- Frequently paired with vascular bioregulators in cardiovascular protocols.
Reported benefits
- Cardiac/myocardial tissue support
- Cardiovascular resilience (proposed)
- Myocardial protein synthesis support
- Short course-based protocol
Possible side effects
- Limited Western clinical data
- Injection site reactions (injectable)
- Unknown long-term effects
Research
- Cardiac peptide bioregulators (2016): Reported to support myocardial tissue function and protein synthesis in regional research studies.
Compare Cardiogen
Research and educational reference only. Not medical advice.